Glioblastoma: From Diagnosis to Treatment

Glioblastoma, also known as GBM, represent 14.9% of all primary brain tumors, and 55.4% of all gliomas. GBM has the highest number of cases of all malignant tumor and has a median survival rate of about 15 months. Patients and family member of a GBM diagnosis have so many questions that can go unanswered. This month’s ABTA webinar focuses on this topic from a patient perspective and discusses the entire journey from the first diagnosis to treatment and prognosis. Dr. Merrell of NorthShore Neurological Institute will elaborate on innovative treatments for GBM including minimally invasive surgery and the latest clinical trials.
0:00 Introduction & Disclosures
3:17 Distribution of Primary Brain Tumors
3:51 Risk Factors
4:54 Glioma Classification
5:51 Pathologic Classification High Grade Gliomas (Grade III and IV)
6:37 Favorable Prognostic Factors
7:37 Molecular classification
9:15 IDHI (Isocitrate Dehydrogenase 1)
10:01 Symptoms suggestive of brain tumors
12:58 The multidisciplinary team
13:53 Newly Diagnosed Tumors
16:56 62 Year-old Male with Headache Surgery Done with Fluorescent Dye
17:30 Fluorescent dye surgery
20:12 Medical Management
20:29 Cerebral edema (brain swelling)
24:10 Antiepileptic Drugs
24:46 Fatigue
26:11 DVT/PE (Blood clots)
27:55 Psychosocial Management
29:19 Historical Timeline of GBM Treatment
30:37 Standard treatment after Surgery, Stupp Regimen
36:16 Standard Treatments: Recurrent
37:33 Bevacizumab (Avastin)
46:50 REACT
50:00 Immune Dysregulation
54:29 Checkpoint Inhibitors
54:58 Checkmate 143 trial
55:31 Attenuated Viral Therapies